Can Soufflé’s REMEDY platform solve RNA drug delivery challenges beyond the liver?
Soufflé secures $135 million as its FSHD RNA therapy trial recruits patients. Examine the REMEDY platform, Bayer partnership and clinical risks.
Pharma & Biotech
Medical Devices & Diagnostics
Bayer’s experimental PET scan detected 94% of cardiac amyloidosis cases. Can it identify the disease earlier?
Bayer's amyloidosis PET tracer showed 94% sensitivity in Phase III. New HFSA analyses examine earlier diagnosis and finerenone treatment gaps.
Features & Analysis
Bayer-backed self-care research highlights referral, affordability and health literacy gaps
Bayer-backed research says self-care can ease health-system strain, but only with safeguards, affordable access and clear referral pathways.
Pharma & Biotech
Could Bayer’s NUBEQA gain a quality-of-life edge after ARACOG cognitive data?
Find out how Bayer’s NUBEQA cognitive data from ARACOG could reshape prostate cancer treatment choices after ASCO 2026.
Pharma & Biotech
Bayer’s asundexian FDA priority review puts Factor XIa inhibition closer to a real stroke prevention test
Bayer needs a new cardiovascular growth engine. Asundexian’s FDA priority review now tests whether Factor XIa can move from promise to practice.
Pharma & Biotech
Why Bayer’s HYRNUO first-line FDA review could reshape HER2-mutated NSCLC treatment sequencing
Bayer has FDA momentum in HER2-mutated lung cancer. The harder test is whether HYRNUO can move earlier without stronger survival data.
Pharma & Biotech
Genethon advances Duchenne gene therapy trial while licensing Pompe tech to Bayer’s AskBio
Genethon advances gene therapies for Duchenne and Pompe disease. Find out what its nonprofit model and AskBio licensing deal mean for rare disease care.
Pharma & Biotech
Can AB-1009 reshape treatment for late-onset Pompe? AskBio prepares for first patient in U.S.
AskBio’s AB-1009 gene therapy for late-onset Pompe secures FDA IND clearance. Find out what this milestone means for AAV innovation and patient outlook.